Agilon Health Reports Q1 2026 Financial Results with Strategic Growth

Agilon Health, Inc. (NYSE: AGL) has announced its first-quarter 2026 financial results, showcasing strategic growth and operational efficiency. The company has raised its full-year guidance for revenues, medical margins, and Adjusted EBITDA. Executive Chairman Ronald A. Williams highlighted significant returns from investments in data, technology, and operational discipline, emphasizing enhancements in clinical pathways and alignment with payors under the Total Care Model.

The leadership transition sees Tim O'Rourke appointed as CEO, promising improved corporate execution and stakeholder value. Q1 2026 financials reveal declines in Medicare Advantage membership by 13% year-over-year and a 7% dip in total revenues, totaling $1.42 billion. However, Agilon reported a 16% increase in medical margin and a substantial 162% rise in Adjusted EBITDA compared to the previous year.

As of March 2026, Agilon's balance sheet reflects $303 million in liquid assets and $32 million in total debt, with $47 million in cash held for its unconsolidated ACO model entities. Revised full-year projections forecast total revenues between $5.68 billion and $5.81 billion, medical margins from $350 million to $400 million, and Adjusted EBITDA between $10 million and $40 million. In Q2 2026, membership stabilization is expected, with projected revenues between $1.435 billion and $1.475 billion and Adjusted EBITDA from $15 million to $25 million.

Agilon focuses on reducing entry costs into new geographies and anticipates expense reductions in this area. The firm aims for growth through enhanced partnerships with physicians and improved margin efficiencies. A conference call to discuss these results is set for May 6, 2026, with a webcast available on Agilon's Investor Relations website.